CHARLES M. BAGLEY JR., M.D.; VINCENT T. DEVITA JR., M.D., F.A.C.P.; COSTAN W. BERARD, M.D.; GEORGE P. CANELLOS, M.D., F.A.C.P.
Thirty-five patients with advanced lymphosarcoma (32 without previous therapy) were treated with intensive 5-day courses of cyclophosphamide and prednisone, with vincristine given on the first day; this was repeated every 3 weeks until complete remission was attained or tumor resistance appeared. There were 20 (57%) complete and 12 (34%) partial responses. Eighty-nine percent of the complete remissions Fasted more than 1 year. Of all 35 patients, 79% lived more than 1 year. Survival of complete responders was significantly better than that of partial responders. Patients with more extensive disease had significantly shorter survival. Toxicity, chiefly leukopenia, was tolerable, reversible, and not cumulative. In inducing frequent and longlasting complete remissions this regimen (CVP) appears superior to those previously reported.
BAGLEY CM, DEVITA VT, BERARD CW, CANELLOS GP. Advanced Lymphosarcoma: Intensive Cyclical Combination Chemotherapy with Cyclophosphamide, Vincristine, and Prednisone. Ann Intern Med. ;76:227–234. doi: 10.7326/0003-4819-76-2-227
Download citation file:
Published: Ann Intern Med. 1972;76(2):227-234.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use